Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 2011. The report details a specific share repurchase transaction executed on April 5, 2011, pursuant to shareholder authority granted at the Annual General Meeting on May 6, 2010.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on capital structure changes related to share buybacks.
- Shares Purchased: 1,000,000 Ordinary shares of 25 pence each.
- Price Range: Highest price paid was 1,225 pence per share; lowest price paid was 1,212.5 pence per share.
- Treasury Shares Held: 493,224,284 shares (representing 8.71% of total issued share capital and 9.54% of total voting rights).
- Shares in Issue: 5,170,117,772 shares (excluding Treasury shares).
Material Changes
The primary material change is the reduction of outstanding share capital through the cancellation of 1,000,000 repurchased shares. This transaction increased the proportion of Treasury shares held by the Company to 8.71% of total issued share capital.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on operational outlook, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities and is made in conformity with the Financial Services Authority's Disclosure and Transparency Rules.
Investor Verification Checklist
- Verify the total number of shares in issue (5,170,117,772) for calculating disclosure thresholds under FSA rules.
- Confirm the updated Treasury share count (493,224,284) and its impact on voting rights (9.54%).
- Review the price paid per share (1,212.5 to 1,225 pence) against market prices on April 5, 2011.